Changes in systemic inflammatory and hemostatic response in patients with co-morbidity of exacerbation of chronic obstructive pulmonary disease, chronic heart failure and obesity
https://doi.org/10.18093/0869-0189-2014-0-6-25-32
Abstract
The aim. The objective of this study was to analyze effects of chronic heart failure (CHF) and obesity on systemic inflammatory and hemostatic response in patients with acute infective exacerbation of chronic obstructive pulmonary disease (COPD). Materials and methods. This cohort study involved 65 patients with infective acute exacerbation of chronic obstructive pulmonary disease (AECOPD) meeting 2 or 3 Anthonisen's criteria. Patients with (n = 53) or without (n = 12) co-morbid CHF and with (n = 20) or without (n = 25) co-morbid obesity were analyzed separately. Markers of systemic inflammation and hemostatic activation were measured. Results. Increased serum concentrations of C-reactive protein, IL-6, endothelin-1, von Willebrand factor, homocysteine, thrombin-antithrombin complex, plasminogen activator inhibitor type 1 were found in AECOPD patients of all subgroups; serum level of tissue factor pathway inhibitor (TFPI) was also increased. These proinflammatory and hypercoagulatory shifts were not related to CHF and obesity. Increased TNF-α level in blood was found only in CHF patients.
About the Authors
A. G. Chuchalin
Federal Institution "Pulmonology Research Institute", Federal Medical and Biological Agency of Russia: 32, build. 4, 11th Parkovaya ul., Moscow, 105077, Russia
Russian Federation
Russian Federation
MD, Professor, Academician of the Russian Science Academy, Director of Federal State Budget institution "Pulmonology Research Institute", Federal Medical and Biological Agency of Russia, the Chairman of the Russian Respiratory Society, Chief Therapeutist and Pneumologist of the Healthcare Ministry of Russian Federation; tel.: (495) 465-52-64
I. Ya. Tseymakh
State Institution "Altay State Medical University", Healthcare Ministry, Russia: 75, Zmeinogorskiy trakt, Barnaul, 656045, Russia
Russian Federation
Russian Federation
PhD, Associate Professor of Chair of Therapy and Family Medicine, Faculty of Postgraduate Education, State Budget High-Level Educational Institution "Altay State Medical University", Healthcare Ministry, Russia; tel.: (3852) 68-50-29, fax: (3852) 68-50-23
A. P. Momot
State Institution "Altay State Medical University", Healthcare Ministry, Russia: 75, Zmeinogorskiy trakt, Barnaul, 656045, Russia;
Altay branch of Federal State Budget Institution "Hematology Scientific center", Healthcare Ministry, Russia: 1, Lyapidevskogo ul., Barnaul, 656024, Russia
Russian Federation
Russian Federation
MD, Director of Altay branch of Federal State Budget Institution "Hematology Scientific center", Healthcare Ministry, Russia; Scientific Advisor of Laboratory of Hematology, Central Scientific Research Laboratory, State Budget High-Level Educational Institution "Altay State Medical University", Healthcare Ministry, Russia; tel.: (3832) 68-98-00
A. N. Mamaev
Altay branch of Federal State Budget Institution "Hematology Scientific center", Healthcare Ministry, Russia: 1, Lyapidevskogo ul., Barnaul, 656024, Russia;
State Institution "Territorial Clinical Hospital": 1, Lyapidevskogo ul., Barnaul, 656024, Russia
Russian Federation
Russian Federation
MD, Senior Researcher of Altay branch of Federal State Budget Institution "Hematology Scientific center", Healthcare Ministry, Russia; Head of Laboratory of Hemostasis, State Budget Clinical Healthcare Institution "Territorial Clinical Hospital"; tel. / fax: (3852) 68-98-80
I. A. Karbyshev
Territorial State Institution"Diagnostic Center of Altay Territory": 5a, Komsomol'skiy prospekt, Barnaul, 656038, Russia
Russian Federation
Russian Federation
Head of Department of Laboratory Diagnosis, Territorial State Budget Healthcare Institution "Diagnostic Center of Altay Territory"; tel.: (3852) 24-46-63, fax: (3852) 26-15-07
G. I. Kostyuchenko
State Institution "Territorial Clinical Hospital": 1, Lyapidevskogo ul., Barnaul, 656024, Russia
Russian Federation
Russian Federation
MD, Professor, Deputy Director for Science of State Budget Clinical Healthcare Institution "Territorial Clinical Hospital"; tel. / fax: (3852) 68-98-56
References
1. Rabe K.F., Wedzicha J.A., Wouters E.F.M. et al. COPD and Comorbidity. Eur. Respir. Soc. Monograph. 2013. DOI: 10.1183/1025448x.erm5913.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2013 [electronic resource]. www.goldcopd.org. Available at: http:// www.goldcopd.org/uploads/users/files/GOLD_Report_2013_ Feb20.pdf
3. Chuchalin A.G., ed. Chronic Obstructive Pulmonary Disease. A monograph. Moscow: Atmosfera; 2008 (in Russian).
4. Avdeev S.N. Chronic obstructive pulmonary disease: acute exacerbation. Pul'monologiya. 2013; 3: 5–19 (in Russian).
5. Wakabayashi K., Gonzalez M., Delhaye C. Impact of ?Chronic Obstructive Pulmonary Disease on Acute–Phase Outcome of Myocardial Infarction. Am. J. Cardiol. 2010; 106 (3): 305–309.
6. Singanayagam A., Schembri S., Chalmers J.D. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. A systematic review and meta–analysis. Ann. Am. Thorac. Soc. 2013; 10 (2): 81–89.
7. Cavaille`s A., Brinchault–Rabin G., Dixmier ?. Comorbidities of COPD. Eur. Respir. Rev. 2013; 22: 454–475.
8. Gunen H., Gulbas G., In E. et al. Venous thromboemboli and exacerbations of COPD. Eur. Respir. J. 2010; 35: 1243–1248.
9. Liu L., Miura K., Fujiyoshi A. et al. Impact of metabolic syndrome on the risk of cardiovascular disease mortality in the United States and in Japan. Am. J. Cardiol. 2014; 113 (1): 84–89.
10. Kuznik B.I. Cellular and Molecular Mechanisms of Hemostasis Regulation in Health and Disease. Chita: Ekspress-izdatel'stvo; 2010 (in Russian).
11. Martin-Ventura J.L., Madrigal-Matute J., Martinez-Pinna R. et al. Erythrocytes, leukocytes and platelets as a source of oxidative stress in chronic vascular diseases: Detoxifying mechanisms and potential therapeutic options. Thromb. Haemost. 2012; 108: 435–442.
12. Högye M., Mándi Y., Csanády M. et al. Comparison of circulating levels of interleukin-6 and tumor necrosis factoralpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. Am. J. Cardiol. 2004; 94 (2): 249–251.
13. Zhengxun Z., Xincan L., Xiaoling C. et al. Relation of QRS duration and TNFA in patients with cardiac desynchronisation in chronic heart failure. Heart. 2011; 97 (Suppl. 3): ?222.
14. National clinical guidelines of Russian Scientific Society of Cardiologists and Society of Heart Failure Specialists on Diagnosis and Treatment of Chronic Heart Failure (the 3rd revision approved by the SHFS Conference on the 15th, December, 2009). Heart Failure. 2010; 11 (57): 3–62. Available at: http://www.scardio.ru/content/images/recommendation/Guidelines_SSHF_rev.3.01_2010.pdf (in Russian).
15. Barkagan Z.S., Momot A.P. Diagnosis and Supervised Therapy of Hemostasis Disorders. Moscow: N'yudiamed; 2008 (in Russian).
16. Momot A.P., ed. Recent Methods for Thrombotic Activity Detection. A Monograph. Barnaul: Izdatel'stvo Altayskogo universiteta; 2011 (in Russian).
17. Marcucci R., Gori A.M., Giannotti F. et al. Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. J. Thromb. Haemost. 2006; 4: 1017–1022.
18. Bendstrup K.E., Gram J., Jensen J.I. Effect of inhaled heparin on lung function and coagulation in healthy volunteers. Eur. Respir. J. 2002; 19: 606–610.
19. Mannucci P.M., Bernardinelli L., Foco L. et al. Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women. J. Thromb. Haemost. 2005; 3: 280–286.
20. Preissner K.T. Adipose tissue-derived PAI-1: A molecular link for thrombo-inflammatory disease states? J. Thromb. Haemost. 2012; 108: 485–492.
Review
For citations:
Chuchalin A.G., Tseymakh I.Ya., Momot A.P., Mamaev A.N., Karbyshev I.A., Kostyuchenko G.I. Changes in systemic inflammatory and hemostatic response in patients with co-morbidity of exacerbation of chronic obstructive pulmonary disease, chronic heart failure and obesity. PULMONOLOGIYA. 2014;(6):25-32. (In Russ.) https://doi.org/10.18093/0869-0189-2014-0-6-25-32
Views:
1047
Email this article 